Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) is BVF Inc. IL’s 5th Largest Position

BVF Inc. IL reduced its stake in shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) by 9.1% in the 4th quarter, HoldingsChannel.com reports. The firm owned 2,796,513 shares of the company’s stock after selling 279,394 shares during the quarter. Mirum Pharmaceuticals comprises approximately 3.9% of BVF Inc. IL’s portfolio, making the stock its 5th largest holding. BVF Inc. IL owned 0.06% of Mirum Pharmaceuticals worth $115,636,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in MIRM. Raymond James Financial Inc. acquired a new position in Mirum Pharmaceuticals in the fourth quarter worth approximately $10,611,000. Marshall Wace LLP increased its stake in shares of Mirum Pharmaceuticals by 641.6% during the 4th quarter. Marshall Wace LLP now owns 175,913 shares of the company’s stock worth $7,274,000 after purchasing an additional 152,191 shares during the last quarter. Price T Rowe Associates Inc. MD raised its holdings in shares of Mirum Pharmaceuticals by 10.8% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 1,422,729 shares of the company’s stock valued at $58,831,000 after purchasing an additional 138,623 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. lifted its stake in shares of Mirum Pharmaceuticals by 162.6% in the 4th quarter. Connor Clark & Lunn Investment Management Ltd. now owns 176,960 shares of the company’s stock valued at $7,317,000 after purchasing an additional 109,585 shares during the last quarter. Finally, Loomis Sayles & Co. L P boosted its holdings in Mirum Pharmaceuticals by 15.8% in the fourth quarter. Loomis Sayles & Co. L P now owns 578,024 shares of the company’s stock worth $23,901,000 after purchasing an additional 78,708 shares in the last quarter.

Mirum Pharmaceuticals Trading Up 0.6 %

Shares of Mirum Pharmaceuticals stock opened at $43.69 on Friday. Mirum Pharmaceuticals, Inc. has a 1 year low of $23.83 and a 1 year high of $54.23. The company’s fifty day simple moving average is $43.23 and its 200-day simple moving average is $44.13. The company has a market cap of $2.16 billion, a price-to-earnings ratio of -21.63 and a beta of 1.00. The company has a current ratio of 3.34, a quick ratio of 3.15 and a debt-to-equity ratio of 1.33.

Mirum Pharmaceuticals (NASDAQ:MIRM) last posted its quarterly earnings results on Wednesday, February 26th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.27) by ($0.22). The company had revenue of $99.41 million during the quarter, compared to analyst estimates of $96.64 million. Mirum Pharmaceuticals had a negative return on equity of 41.22% and a negative net margin of 31.69%. As a group, sell-side analysts expect that Mirum Pharmaceuticals, Inc. will post -1.43 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on the company. Robert W. Baird raised their target price on Mirum Pharmaceuticals from $50.00 to $55.00 and gave the company an “outperform” rating in a report on Thursday, February 27th. HC Wainwright boosted their target price on Mirum Pharmaceuticals from $66.00 to $72.00 and gave the stock a “buy” rating in a report on Friday, February 28th. Ten equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company presently has an average rating of “Buy” and a consensus price target of $58.20.

Insider Activity at Mirum Pharmaceuticals

In other news, CEO Christopher Peetz sold 9,102 shares of the stock in a transaction on Monday, February 3rd. The shares were sold at an average price of $48.22, for a total value of $438,898.44. Following the completion of the transaction, the chief executive officer now owns 115,920 shares in the company, valued at approximately $5,589,662.40. This represents a 7.28 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, SVP Jolanda Howe sold 1,064 shares of Mirum Pharmaceuticals stock in a transaction dated Monday, February 3rd. The shares were sold at an average price of $48.22, for a total transaction of $51,306.08. Following the sale, the senior vice president now owns 4,232 shares in the company, valued at approximately $204,067.04. This trade represents a 20.09 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 105,557 shares of company stock worth $4,726,040 over the last three months. Company insiders own 22.87% of the company’s stock.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.